Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Withdrawals due to adverse events · adults with chronic neuropathic pain
1 finding from 1 review
Withdrawals due to adverse events · Patients with collagenous colitis
Mesalamine showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with collagenous colitis
It is very uncertain whether budesonide changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with collagenous colitis
Boswellia serrata extract showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with fibromyalgia
1 finding from 1 review
Withdrawals due to adverse events · adults with fibromyalgia
1 finding from 1 review
Withdrawals due to adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Withdrawals due to adverse events · children (4 to 18 years) with functional abdominal pain disorders
1 finding from 1 review
Withdrawals due to adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Withdrawals due to adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether anti‐TB therapy changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis
It is very uncertain whether fingolimod 0.5 mg changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)
1 finding from 1 review
Withdrawals due to adverse events · adults with fibromyalgia
1 finding from 1 review
Withdrawals due to adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with osteoarthritis
Chondroitin showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with induction of remission in ulcerative colitis
Type I Interferons may leads to higher withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review